GWM
KYTX icon

GSB Wealth Management’s Kyverna Therapeutics KYTX Stock Holding History

GSB Wealth Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.1K Hold
10,000
– – 0.02% 234
2026
Q1 		$86.3K Buy
+10,000
New +$83.3K 0.02% 223

Other funds holding KYTX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
SIC
Samalin Investment Counsel Chappaqua, New York $320M AUM 20.87% 1-Year Est. Return
CAI
Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return

GSB Wealth Management's KYTX Position: Q2 2026 in Review

GSB Wealth Management held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 10,000 shares worth $89.1K. The position accounts for 0.02% of the portfolio, ranked #234.

GSB Wealth Management first reported a position in KYTX in Q1 2026 and has held it in 2 quarters since. 21 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • GSB Wealth Management held 10,000 shares of Kyverna Therapeutics worth $89.1K as of Q2 2026.
  • GSB Wealth Management left its Kyverna Therapeutics share count unchanged in Q2 2026.
  • Kyverna Therapeutics made up 0.02% of GSB Wealth Management's portfolio in Q2 2026, its #234 holding.
  • GSB Wealth Management first reported a position in Kyverna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 21 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on GSB Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.